Clinical Trial

Efficacy of Ferric Carboxymaltose Versus Iron Sucrose in Non-dialysis Dependent Chronic Kidney Disease Patients

Completed
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if Ferric Carboxymaltose is a safe efficacious alternative to Iron Sucrose for treatment of Iron deficiency anemia in non-dialysis dependent chronic kidney disease patients. The main questions it aims to answer are: * Does Ferric Carboxymaltose causes similar or higher rise in hemoglobin concentration and serum Ferritin and transferrin saturation * What medical problems will participants have when receiving Ferric Carboxymaltose Participants will: * Be administered either Ferric Carboxymaltose or Iron Sucrose * Visit the clinic at day 28 and 56 for checkup and tests * Be monitored for any medical problem during and after infusion
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-20; most recent amendment 2026-04-21.
Status change: Recruiting → Completed 2026-04-21
Status change: Not Yet Recruiting → Recruiting 2025-08-11
Trial Details
NCT Number NCT06994065
Lead Sponsor Sindh Institute of Urology and Transplantation
Conditions Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease
Enrollment 128 participants
Start Date 2025-04-01
Primary Completion 2025-09-30 (estimated)
Study Completion 2025-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-22